Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC NAL-IRI in Peritoneal Carcinomatosis From Gastrointestinal Cancer
NCT05277766Phase 1Active, not recruiting
- Sponsor
- Ghent University Hospital
- Start
- Nov 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nanoliposomal irinotecan in peritoneal carcinomatosis (PC) and gastrointestinal cancer (5 arms), sponsored by Ghent University Hospital. Primary endpoint: Maximally Tolerated Dose at 14 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
peritoneal carcinomatosis (PC)gastrointestinal cancer
Beyond the preview
Go deeper on NCT05277766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277766.